Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499048 | 1.00 | HSD17B10 (0.48) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL15499754 | 1.00 | HSD17B10 (0.48) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL24177004 | 0.94 | HSD17B10 (0.44) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL22434575 | 0.87 | MEN1 (0.40) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL10060132 | 0.87 | HSD17B10 (0.39) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL23105622 | 0.87 | S1PR1 (0.49) | HSD17B10S1PR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL23646017 | 0.85 | HSD17B10 (0.62) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL8742080 | 0.85 | HSD17B10 (0.62) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL5848033 | 0.85 | S1PR1 (0.51) | HSD17B10S1PR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5548993 | 0.84 | S1PR1 (0.54) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455222-B1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20200330624-A1 | IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| WO-2016196628-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | HSD17B10 2398/4885S1PR1 791/4885DRD2 3901/4885 |
| US-20200330624-A1 | IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) | FAP, FIBP, FGFR1 | HSD17B10 4172/4885S1PR1 960/4885DRD2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.